Clinical Trial Update: Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating talimogene laherparepvec in combination with atezolizumab for metastatic triple-negative breast cancer and metastatic colorectal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• T-VEC (talimogene laherparepvec)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Amgen | Conditions: Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-06-09